IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

Détails

ID Serval
serval:BIB_519C67739203
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Périodique
Journal of Hepatology
Auteur⸱e⸱s
Bochud P.Y., Bibert S., Negro F., Haagmans B., Soulier A., Ferrari C., Missale G., Zeuzem S., Pawlotsky J.M., Schalm S., Hellstrand K., Neumann A.U., Lagging M.
ISSN
0168-8278 (Print)
ISSN-L
0168-8278
Statut éditorial
Publié
Date de publication
2011
Volume
55
Numéro
5
Pages
980-988
Langue
anglais
Résumé
Background & Aims: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection. We analyzed the kinetics of HCV RNA during therapy as a function of IL28B SNPs.Methods: IL28B SNPs rs8099917, rs12979860, and rs12980275 were genotyped in 242 HCV treatment-naive Caucasian patients (67% genotype 1, 28% genotype 2 or 3) receiving peginterferon-alpha 2a (180 mu g weekly) and ribavirin (1000-1200 mg daily) with serial HCV-RNA quantifications. Associations between IL28B polymorphisms and early viral kinetics were assessed, accounting for relevant covariates.Results: In the multivariate analyses for genotype 1 patients, the T allele of rs12979860 (T(rs12979860)) was an independent risk factor for a less pronounced first phase HCV RNA decline (log(10) 0.89 IU/ml among T carriers vs. 2.06 among others, adjusted p <0.001) and lower rapid (15% vs. 38%, adjusted p = 0.007) and sustained viral response rates (48% vs. 66%, adjusted p <0.001). In univariate analyses, Trs12979860 was also associated with a reduced second phase decline (p = 0.002), but this association was no longer significant after adjustment for the first phase decline (adjusted p = 0.8). In genotype 2/3 patients, Trs12979860 was associated with a reduced first phase decline (adjusted p = 0.04), but not with a second phase decline.Conclusions: Polymorphisms in IL28B are strongly associated with the first phase viral decline during peginterferon-alpha/ribavirin therapy of chronic HCV infection, irrespective of HCV genotype. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Pubmed
Web of science
Création de la notice
15/12/2011 15:17
Dernière modification de la notice
20/08/2019 14:07
Données d'usage